Immune-related adverse events and neutrophil-to-lymphocyte ratio as prognostic indicators in gynecologic cancer patients receiving pembrolizumab: a real-world analysis

The development of immune-related adverse events and low pretreatment neutrophil-to-lymphocyte ratio independently predicted improved therapeutic response and prolonged survival in gynecologic cancer patients treated with pembrolizumab. Their integration with tumor molecular profiling may optimize monitoring frequency, adjust supportive care measures, and consider treatment modifications based on individual patient risk profiles, thereby enhancing the delivery of immunotherapy in gynecologic cancers without limiting treatment access.